P Pfeiffer
Overview
Explore the profile of P Pfeiffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
247
Citations
4257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, OReilly E, et al.
Ann Oncol
. 2023 Sep;
34(11):987-1002.
PMID: 37678671
No abstract available.
2.
Punt C, Heinemann V, Maughan T, Cremolini C, Van Cutsem E, McDermott R, et al.
ESMO Open
. 2023 Apr;
8(2):101199.
PMID: 37018874
Background: Fluoropyrimidines (FPs) are an essential part of the majority of systemic regimens in the treatment of metastatic colorectal cancer (CRC). The use of the oral FP S-1 has been...
3.
Graversen M, Rouvelas I, Ainsworth A, Bjarnesen A, Detlefsen S, Ellebaek S, et al.
Ann Surg Oncol
. 2023 Mar;
30(7):4433-4441.
PMID: 36867174
Background: Patients with gastric adenocarcinoma (GAC) are at high risk of peritoneal recurrence despite perioperative chemotherapy and radical resection. This study evaluated feasibility and safety of laparoscopic D2 gastrectomy in...
4.
Paulsen N, Pfeiffer P, Ewertz M, Fruekilde P, Feddersen S, Holm H, et al.
ESMO Open
. 2023 Feb;
8(1):100782.
PMID: 36791638
Background: In 2020, the European Medicines Agency recommended testing patients for dihydropyrimidine dehydrogenase (DPD) deficiency before systemic treatment with fluoropyrimidines (FP). DPD activity testing identifies patients at elevated risk of...
5.
Graversen M, Detlefsen S, Ainsworth A, Fristrup C, Knudsen A, Pfeiffer P, et al.
Ann Surg Oncol
. 2023 Jan;
30(5):2634-2644.
PMID: 36602663
Background: Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC) is a local treatment for peritoneal metastasis (PM). Prospective data are scarce and evaluation of treatment response remains difficult. This study evaluated the use...
6.
Carlsson G, Koumarianou A, Guren T, Haux J, Katsaounis P, Kentepozidis N, et al.
ESMO Open
. 2022 Oct;
7(5):100589.
PMID: 36183444
Background: 5-fluorouracil (5-FU) combined with a folate remains an essential treatment component for metastatic colorectal cancer (mCRC). Leucovorin is the folate most often used, but requires intracellular conversion to a...
7.
Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman J, Frodin J, et al.
ESMO Open
. 2022 Jul;
7(3):100427.
PMID: 35798468
Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding...
8.
Van Cutsem E, Danielewicz I, Saunders M, Pfeiffer P, Argiles G, Borg C, et al.
Br J Cancer
. 2022 Apr;
126(11):1548-1554.
PMID: 35440667
Background: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in...
9.
Graversen M, Detlefsen S, Pfeiffer P, Mortensen M
Br J Surg
. 2021 Apr;
108(5):e187-e188.
PMID: 33793765
No abstract available.
10.
Tarpgaard L, Andersen P, Ogaard N, Demuth C, Andersen C, Pfeiffer P
Ann Oncol
. 2021 Mar;
32(6):805-806.
PMID: 33727198
No abstract available.